Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy

Authors

  • Fernanda Costa Svedman Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Theme Cancer, Karolinska University Hospital, Stockholm, Sweden
  • Marie Jalsenius Theme Cancer, Karolinska University Hospital, Stockholm, Sweden
  • Vitali Grozman Section of Thoracic Radiology, Department of Imaging and Physiology, Karolinska University Hospital, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
  • Mattias Bergqvist Biovica International AB, Uppsala Science Park, Uppsala, Sweden
  • Fabian Söderdahl Statisticon AB, Uppsala, Sweden
  • Samuel Rotstein Theme Cancer, Karolinska University Hospital, Stockholm, Sweden
  • Lars Ny Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
  • Suzanne Egyhazi Brage Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
  • Hildur Helgadottir Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Theme Cancer, Karolinska University Hospital, Stockholm, Sweden

DOI:

https://doi.org/10.1080/0284186X.2022.2121615

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2022-09-02

How to Cite

Costa Svedman, F., Jalsenius, M., Grozman, V., Bergqvist, M., Söderdahl, F., Rotstein, S., … Helgadottir, H. (2022). Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy. Acta Oncologica, 61(9), 1116–1120. https://doi.org/10.1080/0284186X.2022.2121615

Issue

Vol. 61 No. 9 (2022): Acta Oncologica

Section

Articles